# Low- vs High-Dose Sirolimus With Prednisolone for KHE and KMP

> **NCT07656909** · PHASE2,PHASE3 · RECRUITING · sponsor: **Yi Ji** · enrollment: 76 (estimated)

## Conditions studied

- Kaposiform Hemangioendothelioma (KHE)
- Kasabach Merritt Phenomenon

## Interventions

- **DRUG:** Sirolimus (RAPAMUNE)

## Key facts

- **NCT ID:** NCT07656909
- **Lead sponsor:** Yi Ji
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-16
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 76 (ESTIMATED)
- **Last updated:** 2026-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07656909

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07656909, "Low- vs High-Dose Sirolimus With Prednisolone for KHE and KMP". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07656909. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*